D053614Chemicals & DrugsD08.811.913.696.620.682.725.124.200D12.776.476.393.200D12.776.624.664.700.117680.997571Janus Kinase 2cmhprofilesont:personsuffixperson suffixFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMD, MPHAlanGamisAlan S. Gamis0.000000000000000.0000000000000049Gamis, Alan0000-0003-1513-2893Chief, Section of Oncology2Associate Professor1Professor17644747Norton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas PBloodNorton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas P. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007 Aug 01; 110(3):1077-9.Blood2007-08-01T00:00:002007Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.0.2066550.008886396research area of0.5348960.035632110subject area forPathology and Laboratory MedicinePediatricsResearchClinicalMD, FASNTarakSrivastavaTarak Srivastava39.08346750000000-94.5771129000000043Srivastava, TarakPediatric NephrologyChildren's Mercy Kansas CityMD, PhD, FCAPMidhatFarooqiMidhat Farooqi0.000000000000000.00000000000000161Farooqi, Midhat0000-0002-5238-1349Director, Molecular Oncology, Center for Pediatric Genomic Medicine25843671Sharma M, Zhou J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, Savin VJTranslational research : the journal of laboratory and clinical medicineSharma M, Zhou J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, Savin VJ. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. 2015 Oct; 166(4):384-98.Transl Res2015-03-16T00:00:002015Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.28951873Savin VJ, Sharma M, Zhou J, Genochi D, Sharma R, Srivastava T, Ilahe A, Budhiraja P, Gupta A, McCarthy ETBioMed research internationalSavin VJ, Sharma M, Zhou J, Genochi D, Sharma R, Srivastava T, Ilahe A, Budhiraja P, Gupta A, McCarthy ET. Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. Biomed Res Int. 2017; 2017:6232616.Biomed Res Int2017-08-10T00:00:002017Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.33661568Dermott SM, Kucine N, Farooqi MS, Li W, Silvey MPediatric blood & cancerDermott SM, Kucine N, Farooqi MS, Li W, Silvey M. Polycythemia vera in a 2-year-old child with a JAK2 exon 12 deletion. Pediatr Blood Cancer. 2021 07; 68(7):e28994.Pediatr Blood Cancer2021-03-04T00:00:002021Polycythemia vera in a 2-year-old child with a JAK2 exon 12 deletion.PhDLauraRamseyLaura Ramsey0.000000000000000.00000000000000221Ramsey, Laura0000-0001-6417-3961Doctoral Research Facultytrue1Doctoral Research FacultyDoctoral Research Faculty24268771Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RWCell reportsWaibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013 Nov 27; 5(4):1047-59.Cell Rep2013-11-21T00:00:002013Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.PhDBrookeFridleyBrooke Fridley0.000000000000000.00000000000000222Fridley, BrookeDirector, Biostatistics and Epidemiology Coretrue1Director, Biostatistics and Epidemiology CoreDirector, Biostatistics and Epidemiology Coretrue1Director, Molecular Oncology, Center for Pediatric Genomic MedicineDirector, Molecular Oncology, Center for Pediatric Genomic Medicinetrue1Chief, Section of OncologyChief, Section of Oncologytrue1Pediatric NephrologyPediatric Nephrology